Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: A case report

Ezponda,Ana; González De La Huebra,Ignacio; Calvo,Marta; Idoate,Miguel Ángel; Vivas,Isabel

doi:10.3892/ol.2018.9114

Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: A case report

Authors:
- Ana Ezponda
- Ignacio González De La Huebra
- Marta Calvo
- Miguel Ángel Idoate
- Isabel Vivas
View Affiliations

Affiliations: Department of Radiology, Clínica Universidad de Navarra, Pamplona 31008, Spain, Department of Pathology, Clínica Universidad de Navarra, Pamplona 31008, Spain
Published online on: July 10, 2018 https://doi.org/10.3892/ol.2018.9114
Pages: 4043-4048

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pazopanib is the first multitargeted tyrosine‑kinase inhibitor approved for the treatment of patients with advanced non‑adipocytic soft tissue sarcoma (STS). It has been demonstrated to improve progression‑free survival without impairing health‑associated quality of life. However, Pazopanib is associated with several adverse side effects associated with inhibition of the vascular endothelial growth factor receptor. These include hepatotoxicity, as manifested by abnormal liver function tests. To the best of our knowledge, the current study presents the first case of a patient with recurrent STS who developed biopsy proven Pazopanib‑induced chronic active hepatitis and whose previous computed tomography examination demonstrated multiple hypervascular liver lesions. These lesions were indistinguishable from metastases and to the best of our knowledge, have not been described previously. These lesions therefore appear to be a novel finding of Pazopanib‑induced chronic active hepatitis. It is crucial to be aware of this unusual finding within a clinical setting, to avoid overstaging and early discontinuation of effective treatment.

View Figures

View References

1	Clark MA, Fisher C, Judson I and Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med. 353:701–711. 2005. View Article : Google Scholar : PubMed/NCBI
2	Zagars GK, Mullen JR and Pollack A: Malignant fibrous histiocytoma: Outcome and prognostic factors following conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 34:983–994. 1996. View Article : Google Scholar : PubMed/NCBI
3	Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, et al: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organitation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 23:576–584. 2005. View Article : Google Scholar : PubMed/NCBI
4	Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, et al: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol. 27:4188–4196. 2009. View Article : Google Scholar : PubMed/NCBI
5	Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
6	DuBois S and Demetri G: Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 109:813–819. 2007. View Article : Google Scholar : PubMed/NCBI
7	Sleijfer S, van der Graaf WT and Blay JY: Angiogenesis inhibition in non-GIST soft tissue sarcomas. Oncologist. 13:1193–1200. 2008. View Article : Google Scholar : PubMed/NCBI
8	Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG and Eisenberg B: Vascular endothelial growth factor and soft tissue sarcomas: Tumor expression correlates with grade. Ann Surg Oncol. 8:260–267. 2001. View Article : Google Scholar : PubMed/NCBI
9	Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, et al: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 27:3126–3132. 2009. View Article : Google Scholar : PubMed/NCBI
10	van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppy Y, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kasper B, Sleijfer S, Litière S, Marreaud S, Verweij J, Hodge RA, Bauer S, Kerst JM and van der Graaf WT: Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. 25:719–724. 2014. View Article : Google Scholar : PubMed/NCBI
12	Coens C, van der Graaf WT, Blay JY, Chawla SP, Judson I, Sanfilippo R, Manson SC, Hodge RA, Marreaud S, Prins JB, et al: Health-related quality-of- life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Global Network Study (EORTC 62072). Cancer. 121:2933–2941. 2015. View Article : Google Scholar : PubMed/NCBI
13	Klempner SJ, Choueiri TK, Yee E, Doyle LA, Schuppan D and Atkins MB: Severe pazopanib-induced hepatotoxicity: Clinical and histologic course in two patients. J Clin Oncol. 30:e264–e286. 2012. View Article : Google Scholar : PubMed/NCBI
14	GlaxoSmithKline: Votrient (pazopanib) tablets prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf
15	Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D and Cascinu: Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. Int J Cancer. 135:763–773. 2014. View Article : Google Scholar : PubMed/NCBI
16	Chen HX and Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kapadia S, Hapani S, Choueiri TK and Wu S: Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 52:1202–1212. 2013. View Article : Google Scholar : PubMed/NCBI
18	Klapko O, Ghoulam E, Jakate S, Eswaram S and Usha L: Anastrozole-induced autoimmune hepatitis: A rare complication of breast cancer therapy. Anticancer research. 37:4173–4176. 2017.PubMed/NCBI
19	Vilgrain V, Lagadec M and Ronot M: Pitfalls in Liver Imaging 2016. Radiology. 278:34–51. 2016. View Article : Google Scholar : PubMed/NCBI
20	Silva AC, Evans JM, McCullough AE, Jatoi MA, Vargas HE and Hara AK: MR Imaging of hypervascular liver masses: a review of current techniques. Radiographics. 29:385–402. 2009. View Article : Google Scholar : PubMed/NCBI